Cockroach Immunotherapy in Children and Adolescents — CRITICAL  

Persistent Asthma Clinical Trial

Official title: Cockroach Immunotherapy in Children and Adolescents

Status Completed

Clinical Trial Summary

Scientific evidence has shown that, over the past two decades, the combination of cockroach allergy and cockroach exposure is one of the most important factors contributing to the dramatic increase in asthma morbidity seen in inner city children with asthma. Therefore, a major goal of the Inner City Asthma Consortium (ICAC) is to evaluate the efficacy of cockroach immunotherapy in inner city asthma.

The primary objective of the study is to determine if the response to nasal allergen challenge (NAC) will be changed with treatment with cockroach subcutaneous immunotherapy (SCIT) treatment.

Clinical Trial Description

This is a 1:1 randomized, double-masked (blind), placebo-controlled, multicenter trial with 2 treatment arms:

• German Cockroach Subcutaneous Immunotherapy (SCIT) + guideline-based standard asthma care, OR

• Placebo (for German Cockroach Subcutaneous Immunotherapy [SCIT]) + guideline-based standard asthma care

Eighty participants 8 to 17 years of age who are sensitized to cockroach, have asthma, and a positive cockroach Nasal Allergen Challenge (NAC) before treatment randomization will be enrolled. ;

Related Conditions & MeSH terms

• Asthma
• Persistent Asthma

• NCT number: NCT03541187
• Study type: Interventional
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Status: Completed
• Phase: Phase 2
• Start date: July 16, 2018
• Completion date: June 3, 2022